Cardiovascular and selected comorbidities in early arthritis and XXXX , a comparative study: results from the ESPOIR and DESIR cohorts.

@entity1 @entity101 @entity6 @entity301 @entity5 @entity281 @entity1691 @entity65 @entity378 @entity309
OBJECTIVES: To investigate the prevalence of comorbidities in early @entity309 (ERA) and early @entity1691 (ESpA) versus the general population. METHODS: Baseline data of 689 @entity1 with ERA from the Etude et Suivi des Polyarthrites Indiff  renci  es R  centes (ESPOIR) cohort (age 48.2  12.1   years, symptoms duration 14.2  14.5   weeks) and 645 @entity1 with ESpA from Devenir des Spondylarthropathies Indiff  renci  es R  centes (DESIR; age 32.8  8.4   years, axial symptoms duration 79.0  45.7   weeks) were analysed. @entity65 ( @entity65 ), @entity281 and @entity5 were determined in each cohort. The prevalence (95% CI) of several comorbidities was compared with that in the French general population. For @entity1 without @entity65 , the 10-year risk of developing @entity65 was calculated using the Framingham and SCORE equations. The heart age was calculated using the 2008 Framingham points system. RESULTS: 42% of @entity1 with ERA and 20.3% of @entity1 with ESpA had at least 1 comorbidity; the most common were @entity101 ( @entity101 ) and dyslipidaemia. @entity101 prevalence (95% CI) in ERA (18.2% (15.5% to 21.3%)), but not in ESpA (5.08% (3.57% to 7.14%)), was significantly increased (p<0.05) compared with the general population (7.58%). Prevalence of @entity378 history was higher in ERA (4.7% (3.3% to 6.6%)), and ESpA (0.99% (0.4% to 2.3%)) than in the general population (0.02%; both p<0.05). No differences were observed in @entity5 , @entity301 or @entity6 . In ERA, among @entity1 without a history of @entity65 , an intermediate to high @entity65 risk was found. The heart age exceeded the real age by 4.1  9.6   years in ERA and by 2.1  7.0   years in ESpA (p<0.001). CONCLUSIONS: We found an increased prevalence of @entity101 and @entity378 history in ERA and ESpA, and an increased @entity65 risk. These results should prompt rheumatologists to check these comorbidities early in the disease.
